Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp162 | Cancer and bone: basic, translational and clinical | ECTS2013

Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer: the ZOTECT Study

Hadji Peyman , Ziller May , Maurer Tobias , Autenrieth Michael , Muth Mathias , Ruebel Amelie , May Christoph , Birkholz Katrin , Diebel Erhardt , Gleissneer Jochen , Rothe Peter , Gschwend Juergen E

Introduction: The prospective, single-arm, open-label ZOTECT study was designed to assess the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients with bone metastases.Methods: Patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) who have not received bisphosphonates for ≥6 months were enrolled at 98 sites in Ge...

ba0001pp469 | Other diseases of bone and mineral metabolism | ECTS2013

MEPE-derived ASARM peptide impairs mineralization in tooth models of X-linked hypophosphatemia

Salmon Benjamin , Bardet Claire , Khaddam Mayssam , Baroukh Brigitte , Lesieur Julie , Denmat Dominique Le , Nicoletti Antonino , Poliard Anne , Rowe Peter S , Linglart Agnes , McKee Marc D , Chaussain Catherine

Mutations in the PHEX gene cause X-linked familial hypophosphatemic rickets (XLH) with severe bone (osteomalacia) and tooth abnormalities being the distinguishing features of this disease. The PHEX mutations lead to an increase in ASARM peptides (acidic serine- and aspartate-rich motif) and osteopontin fragments which inhibit bone extracellular matrix mineralization. MEPE-derived ASARM has been shown to accumulate in tooth dentin of patients with XLH where it may impair dentin...

ba0002p33 | (1) | ICCBH2013

Patients with mutations in PHEX or FGF23 share FGF23 excess but present distinct bone and mineral metabolism features

Theret Claire , Esterle Laure , Souchon Pierre-Francois , Allain-Launay Emma , Roussey Gwennaelle , Deschenes Georges , Chaussain Catherine , Rothenbuhler Anya , Prie Dominique , Silve Caroline , Kamenicky Peter , Linglart Agnes

Mutations in PHEX and specific missense mutations of FGF23 result in elevated circulating FGF23 and hypophosphatemic rickets, respectively X-linked hypophosphatemic rickets (XLHR) and autosomal dominant HR (ADHR). FGF23, secreted by osteoblasts and osteocytes, regulates phosphate handling and vitamin D metabolism through its action on kidney. Extra renal effects of FGF23, including bone, have been very recently suspected mainly from overexpression or underexpression of FGF23 i...

ba0003pp255 | Osteoporosis: evaluation and imaging | ECTS2014

Dynamic changes in bone marrow adiposity during the menstrual cycle

Veldhuis-Vlug Annegreet , Limonard Eelkje , van Dussen Laura , Runge Jurgen , Tanck Michael , Endert Erik , Heijboer Annemieke , Fliers Eric , Hollak Carla , Akkerman Erik , Bisschop Peter

Background: Bone marrow (BM) adiposity is inversely related to bone mineral density and increases with ageing and menopause. We previously observed that the variation in BM fat fraction was more pronounced in premenopausal women compared to men and postmenopausal women. We hypothesized that the variation in BM fat fraction in premenopausal women is associated with hormonal variations during the menstrual cycle.Objective: To investigate the dynamic change...

ba0003pp360 | Osteoporosis: treatment | ECTS2014

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

Hawley Sam , Wallace Gemma , Javaid M Kassim , Rubin Katrine , Judge Andrew , Vestergaard Peter , Eastell Richard , Diez-Perez Adolfo , Arden Nigel K , Cooper Cyrus , Prieto-Alhambra Daniel , Abrahamsen Bo

Objective: To identify predictors of inadequate response to oral bisphosphonate therapy, defined as the incidence of ≧2 fractures while on treatment among incident oral bisphosphonate users with high refill compliance (≧80%).Material and methods: Data from computerized records and pharmacy invoices were obtained from SIDIAP (Catalonia, E) and Danish Health Registries (DK) for all incident users of oral bisphosphonates in 2006–2007 and 2000&#15...

ba0004oc10 | (1) | ICCBH2015

Lack of PEDF within the bone matrix is associated with osteoidosis and abnormally high bone mineral content

Fratzl-Zelman Nadja , Schmidt Ingo , Roschger Paul , Roschger Andreas , Reich Adi , Glorieux Francis H. , Wagermaier Wolfgang , Fratzl Peter , Klaushofer Klaus , Marini Joan C. , Rauch Frank

Background and methods: Pigment epithelium-derived factor (PEDF) is a potent antiangiogenic factor, ubiquitously expressed and secreted in human tissues. Hypertrophic cartilage and osteoblasts express PEDF that binds to type I collagen and glycosaminoglycans in the extracellular matrix. Two rare forms of osteogenesis imperfecta (OI) with intact collagen synthesis are associated with PEDF deficiency. Histological observations revealed excessive osteoid formation and prolonged m...

ba0005p114 | Cancer and bone: basic, translational and clinical | ECTS2016

Increased zinc accumulation in mineralized osteosarcoma tissue

Rauwolf Mirjam , Pemmer Bernhard , Roschger Andreas , Turyanskaya Anna , Simon Rolf , Lang S. , Puchner S E , Windhager Reinhard , Klaushofer Klaus , Wobrauschek Peter , Hofstaetter Jochen G , Roschger Paul , Streli Christina

Abnormal tissue levels of certain trace elements such as Zinc (Zn) were reported in various types of cancer. Little is known about the role of Zn in osteosarcoma.Using confocal synchrotron radiation micro X-ray fluorescence analysis, we characterized the spatial distribution of Zn in high-grade (G3) sclerosing osteosarcoma of nine patients (4 f/5 m; 7 knee/1 humerus/1 femur) following chemotherapy and wide surgical resection. The study was done in accord...